SCHEMBL20964680

SCHEMBL20964680

Cc1noc(C)c1CSc1ccccc1C(=O)N1CCN(c2cccc(Cl)c2)CC1

nearest known ligand 0.82

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.82
TSHR P16473 6/20 0.82
ALDH1A1 P00352 4/20 0.82
SMN1; SMN2 Q16637 3/20 0.82
HTT P42858 2/20 0.61
KMT2A Q03164 2/20 0.61
MEN1 O00255 1/20 0.61
MAPK1 P28482 1/20 0.61
NPC1 O15118 2/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
ALOX15 P16050 1/20 0.51
RAB9A P51151 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
POLB P06746 1/20 0.51
PKM P14618 1/20 0.51
THRB P10828 1/20 0.50
MAPT P10636 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20964645 0.91 LMNA (0.82) LMNATSHRALDH1A1SMN1; SMN2HTT
SCHEMBL19745442 0.91 LMNA (1.00) LMNATSHRALDH1A1SMN1; SMN2HTT
SCHEMBL20964601 0.89 LMNA (0.80) LMNATSHRALDH1A1SMN1; SMN2HTT
SCHEMBL25057031 0.89 LMNA (0.76) LMNATSHRALDH1A1SMN1; SMN2HTT
SCHEMBL20964539 0.88 TSHR (0.77) LMNATSHRALDH1A1SMN1; SMN2HTT
SCHEMBL30428560 0.88 TSHR (0.77) LMNATSHRALDH1A1SMN1; SMN2HTT
SCHEMBL20964627 0.87 LMNA (0.62) LMNATSHRALDH1A1SMN1; SMN2HTT
SCHEMBL20964719 0.86 SMN1; SMN2 (0.77) LMNATSHRALDH1A1SMN1; SMN2HTT
SCHEMBL25057030 0.86 LMNA (0.73) LMNATSHRALDH1A1SMN1; SMN2HTT
SCHEMBL20964665 0.84 LMNA (0.62) LMNATSHRALDH1A1SMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10851096-B2 Aryl and heteroaryl amides for use as anti-proliferative, anti-thrombotic, and anti-viral agents RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2020-12-01 US disclosed
US-20190127361-A1 Therapeutic Compounds RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2019-05-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190127361-A1 Therapeutic Compounds SDHA, SLC10A1, SERPINC1 LMNA 1413/4885TSHR 3423/4885ALDH1A1 141/4885
US-10851096-B2 Aryl and heteroaryl amides for use as anti-proliferative, anti-thrombotic, and anti-viral agents SERPINC1, F12, RPL35 LMNA 897/4885TSHR 2794/4885ALDH1A1 870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.